NCT07245563

Brief Summary

  1. 1.To determine the susceptibility pattern of our local isolated Candida strains which is essential for optimal management of fungal infection.
  2. 2.Detection of biofilm formation by conventional and molecular methods
  3. 3.Comparison between C. albicans and non-albicans in the prevalence of biofilm formation and biofilm -forming genes
  4. 4.Find the association between antifungal resistance and biofilm formation in candida strains isolated from patients
  5. 5.Determination of clinical factors associated with occurrence of infections.

Trial Health

65
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
300

participants targeted

Target at P75+ for all trials

Timeline
5mo left

Started Dec 2025

Shorter than P25 for all trials

Status
not yet recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress47%
Dec 2025Oct 2026

First Submitted

Initial submission to the registry

October 2, 2025

Completed
2 months until next milestone

First Posted

Study publicly available on registry

November 24, 2025

Completed
26 days until next milestone

Study Start

First participant enrolled

December 20, 2025

Completed
9 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

September 20, 2026

Expected
22 days until next milestone

Study Completion

Last participant's last visit for all outcomes

October 12, 2026

Last Updated

November 24, 2025

Status Verified

November 1, 2025

Enrollment Period

9 months

First QC Date

October 2, 2025

Last Update Submit

November 17, 2025

Conditions

Outcome Measures

Primary Outcomes (2)

  • To asses the prevalence of candida species as a cause of infection in patient in hematology intinsive care unit

    1 year

  • To asses the prevalence of genes responsible for biofilm formation in different candida species

    1 year

Eligibility Criteria

Sexall
Healthy VolunteersNo
Age GroupsChild (0-17), Adult (18-64), Older Adult (65+)
Sampling MethodProbability Sample
Study Population

patients admitted to hematology intensive care

You may qualify if:

  • Eligible participants in the study were those with invasive infection and had one or more of this criteria :
  • oSuppressed general body immunity.
  • oSuppressed local body immunity as a result of trauma or invasive procedures.
  • oResistant to antibiotic therapy.
  • oNegative samples for bacterial examination and culture.
  • Critical life threatening infect

You may not qualify if:

  • Patients who received antifungal therapy within 3 days prior to sample collection.
  • Resistant to antibiotic therapy.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Biospecimen

Retention: SAMPLES WITH DNA

sputum,urine and blood

MeSH Terms

Conditions

Candidiasis

Condition Hierarchy (Ancestors)

MycosesBacterial Infections and MycosesInfections

Central Study Contacts

mennat-allah khaled abdelhady

CONTACT

Study Design

Study Type
observational
Observational Model
OTHER
Time Perspective
CROSS SECTIONAL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
demonstrator at microbiology department at Assiut university

Study Record Dates

First Submitted

October 2, 2025

First Posted

November 24, 2025

Study Start

December 20, 2025

Primary Completion (Estimated)

September 20, 2026

Study Completion (Estimated)

October 12, 2026

Last Updated

November 24, 2025

Record last verified: 2025-11